| Literature DB >> 24144420 |
Megan J Osmond-McLeod1, Ronald I W Osmond, Yalchin Oytam, Maxine J McCall, Bryce Feltis, Alan Mackay-Sim, Stephen A Wood, Anthony L Cook.
Abstract
BACKGROUND: Inhaled nanoparticles have been reported in some instances to translocate from the nostril to the olfactory bulb in exposed rats. In close proximity to the olfactory bulb is the olfactory mucosa, within which resides a niche of multipotent cells. Cells isolated from this area may provide a relevant in vitro system to investigate potential effects of workplace exposure to inhaled zinc oxide nanoparticles.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24144420 PMCID: PMC4016547 DOI: 10.1186/1743-8977-10-54
Source DB: PubMed Journal: Part Fibre Toxicol ISSN: 1743-8977 Impact factor: 9.400
Figure 1Experimental overview. Nanoparticles were characterised as powders or dispersions in aqueous media (top left), and also as dispersions in DMEM cell-culture medium (top right). An initial concentration response curve was generated to select an appropriate treatment concentration that elicited a mechanistic response in hONS cells for at least one of the ZnO products. hONS cells were exposed to ZnO products at the selected concentration (25 μg/mL) for up to 24 h, after which the cellular responses to treatment were measured by a variety of assays. ‡ Cells from four human donors, A, B, C and D, each in three replicate wells for each treatment time-point (2 h, 6 h and 24 h); * Donor A cells, in three replicate wells for each treatment time-point (2 h and 6 h); † Donor A cells, in four replicate wells for each treatment time-point (2 h, 4 h, 6 h, 8 h, and 10 h); ** Donor A cells, in four replicate wells for each treatment time-point (2 h and 6 h).
Physical and chemical properties of the four types of ZnO nanoparticles
| None | None | Triethoxycaprylylsilane | Dimethoxydiphenylsilane/Triethoxycaprylylsilane crosspolymer | N/A | ||
| EHDA3001 | 4051 | CNHE0602 | FCHE1301 | N/A | ||
| N/A | ||||||
| | | | ||||
| 14.5 | 32.5 | 14.4 | 10.8 | N/A | ||
| | 12.3 | 28.2 | 15.4 | 12.7 | | |
| N/A | ||||||
| | ||||||
| BD | BD | BD | BD | N/A | ||
| | ||||||
| | ||||||
| | ||||||
| | ||||||
| | ||||||
| | ||||||
| N/A | ||||||
| | | |||||
| | | |||||
Nanoparticles were characterised as dry powders or as dispersions in either water or cell-culture medium. For measurements of hydrodynamic diameters of particles or agglomerates by DLS, polydispersity indices (PDI) are given in parentheses. N/A not applicable; NS not significant; BD below detection; * statistically significant compared to negative control (saline only); + errors are standard errors of means.
Figure 2Nanoparticle morphologies and size distributions. TEM images of ZnO nanoparticles used in this study alongside boxplots showing the distributions of particle lengths and widths (A. Z-COTE; B. HP1; C. MAX) or diameter (D. Nanosun), depending on whether particles were mainly rod-shaped or spherical, respectively. 90–300 measurements were made for each dimension. The vertical line in the box represents the median value and the edges of the box represent the lower and upper quartiles. The whiskers at the ends of the horizontal lines represent minimum and maximum values. Scale bar for TEM images = 200 nm.
Figure 3Levels of the cytokines IL-6 and IL-8 in hONS cells treated with ZnO nanoparticles. hONS cells from donor A were placed in three replicate wells for each ZnO treatment time-point (2 h and 6 h). Results were averaged and expressed relative to levels in time-matched untreated cells set as 100%. * Indicates statistical significance relative to untreated cells.
Figure 4Phosphorylation of key proteins from four major cell-signalling pathways in hONS cells treated with ZnO nanoparticles. hONS cells from donor A were placed in four replicate wells for each ZnO treatment time-point (2, 4, 6, 8 and 10 h). Levels of phosphorylation of proteins involved in the selected cell-signalling pathways in cell lysates were averaged and expressed as the percentage of time-matched untreated cells set as 100%. The four cell-signalling pathways are I DNA Damage; II NFκB; III MAPK; IV AKT. Data used to generate this figure, and associated standard errors of means and statistical significance, are supplied separately in Additional file 2: Table S1.
Canonical pathways most significantly perturbed at the transcriptional level in hONS cells exposed to ZnO nanoparticles
| Aldosterone signalling in epithelial cells | 1.97E - 10 | Nucleotide excision repair pathway | 1.30E - 05 | |
| NRF2-mediated oxidative stress response | 1.33E - 08 | Endoplasmic reticulum stress pathway | 2.75E - 04 | |
| Protein ubiquitination pathway | 3.66E - 06 | Protein ubiquitination pathway | 6.82E - 04 | |
| Glucocorticoid receptor signalling | 3.53E - 05 | Ubiquinone bisoynthesis | 9.82E - 04 | |
| Huntingtons’s disease signalling | 7.91E - 05 | Assembly of RNA Polymerase II complex | 1.24E - 03 | |
| Aldosterone signalling in epithelial cells | 4.70E - 07 | Ubiquinone biosynthesis | 9.92E - 12 | |
| NRF2-mediated oxidative stress response | 1.31E - 05 | Mitochondrial dysfunction | 4.00E - 11 | |
| IL-17A signalling in fibroblasts | 6.40E - 05 | Nucleotide excision repair pathway | 5.92E - 11 | |
| Production of nitric oxide and reactive oxygen species in macrophages | 1.17E - 04 | Oxidative phosphorylation | 2.70E - 09 | |
| Glucocorticoid receptor signalling | 1.87E - 04 | Protein ubiquitination pathway | 1.60E - 08 | |
| Aldosterone signalling in epithelial cells | 4.12E - 07 | Glucocorticoid receptor signalling | 1.25E - 07 | |
| NRF2-mediated oxidative stress response | 1.17E - 06 | Aldosterone signalling in epithelial cells | 5.85E - 06 | |
| Glucocorticoid receptor signalling | 1.50E - 04 | Protein ubiquitination pathway | 8.79E - 06 | |
| IL - 17A signalling in fibroblasts | 4.88E - 04 | NRF2-mediated oxidative stress response | 7.27E - 05 | |
| Protein ubiquitination pathway | 9.24E - 04 | Assembly of RNA Polymerase II complex | 9.05E - 05 | |
| Aldosterone signalling in epithelial cells | 7.40E - 04 | Hereditary breast cancer signalling | 6.11E - 06 | |
| NRF2-mediated oxidative stress response | 1.01E - 03 | Aminoacyl-tRNA biosynthesis | 4.24E - 05 | |
| IL-10 signalling | 2.71E - 03 | Glucocorticoid receptor signalling | 5.61E - 05 | |
| Protein ubiquitination pathway | 2.85E - 03 | Mismatch repair in eukaryotes | 7.59E - 05 | |
| Endothelin-1 signalling | 1.48E - 02 | Nucleotide excision repair pathway | 1.04E - 04 |
Figure 5Map of differential transcript activity in hONS cells treated with ZnO nanoparticles. hONS cells from donor A were assessed in quadruplicate wells for each ZnO treatment time-point (2 h and 6 h). Differentially-expressed transcripts were grouped according to function, ordered alphabetically within each function, and arrayed alongside one another for each of the treatment data sets. The sorted files were then uploaded to the web-based prettygraph (http://www.prettygraph.com) to generate colour-coded maps for the aligned transcriptional profiles across all treatments. Green indicates up-regulated transcripts, red indicates down-regulated transcripts, and black signifies little difference from untreated cells (although still reaching statistical significance where p<0.05). White gaps signify treatments where transcripts were not differentially-expressed relative to untreated cells. The bar at the right hand-side shows the colour-code for the magnitude of the log ratio.
Figure 6VENN diagrame showing numbers of unique or shared transcripts within and between different ZnO treatments at 2 h and 6 h. Numbers indicate differentially-expressed transcripts, graphed according to whether they occurred uniquely within one treatment (unshared VENN), or whether they were differentially activated by two or more of the treatments (intersecting VENN). Blank intersections indicate that no genes were unique to that intersection or treatment.
Figure 7Changes in cell function in hONS cells treated with ZnO nanoparticles. For each ZnO treatment at each time-point (2 h, 6 h and 24 h), the responses of hONS cells from donors A, B, C and D, each seeded in three replicate wells, were averaged and expressed as the percentage of time-matched untreated cells set as 100%. Data used to generate this figure, and associated standard errors of means and statistical significance, are supplied separately in Additional file 3: Table S2.